Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis | Neurodegenerative Disease Management
Prediction of the complex structure of patisiran (Onpattro). The input... | Download Scientific Diagram
Onpattro, INN - patisiran
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis | springermedizin.de
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs | Nature Nanotechnology
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
FULL PRESCRIBING INFORMATION: CONTENTS*
Gene silencing through RNA interference scores first drug approval - Genetic Literacy Project
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis | SpringerLink
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs - ScienceDirect
These highlights do not include all the information needed to use ONPATTRO® safely and effectively. See full prescribing information for ONPATTRO. ONPATTRO (patisiran) lipid complex injection, for intravenous useInitial U.S. Approval: 2018
Envolve Pharmacy Solutions Criteria Working Template ACCESSIBLE
Reimbursement Guide for ONPATTRO® (patisiran)
Advances in oligonucleotide drug delivery | Nature Reviews Drug Discovery
ONPATTRO (patisiran) small interfering RNA for Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Recent advances in siRNA delivery mediated by lipid-based nanoparticles - ScienceDirect
ONPATTRO® (patisiran) Dosing and Preparation Guide
Structure of patisiran. | Download Scientific Diagram
Onpattro, INN - patisiran
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran | SpringerLink
